Q3 2025 Mckesson Corp Earnings Call Transcript
Key Points
- McKesson Corp (MCK) reported strong third-quarter results with an 18% increase in revenue to $95.3 billion and a 16% growth in adjusted operating profit to $1.5 billion.
- The company announced the acquisition of a controlling interest in PRISM Vision, enhancing its specialty services platform and capabilities in ophthalmology and retina management.
- McKesson Corp (MCK) has seen strong performance in its US Pharmaceutical and Prescription Technology Solutions segments, with double-digit growth in operating profit.
- The company is investing in strategic growth pillars such as oncology and biopharma services, with significant expansion in the US Oncology Network and clinical trial services.
- McKesson Corp (MCK) is implementing cost optimization initiatives expected to deliver $100 million in savings, enhancing operational efficiencies across its segments.
- The Medical Surgical segment experienced lower-than-anticipated growth due to a softer illness season, impacting demand for seasonal vaccines and testing.
- Operating expenses increased by 2%, driven by higher costs to support growth in the US Pharmaceutical segment.
- The effective tax rate increased to 23.9% from 10.6% in the prior year, impacting net earnings.
- Free cash flow was negative $2.6 billion for the quarter, influenced by timing shifts in cash flow and capital expenditures.
- The company faces challenges in the primary care channel with lower volumes, impacting the Medical-Surgical Solutions segment.
Welcome to McKesson's third-quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being recorded.
At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations. Please go ahead.
Thank you, operator. Good afternoon, and welcome, everyone, to McKesson's third-quarter fiscal 2025 earnings call. Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. Brian will lead off, followed by Britt, and then we will move to a question-and-answer session.
Today's discussion will include forward-looking statements, such as forecast about McKesson's operations and future results. Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at investor.mckesson.com, and to the Risk Factors section of our most recent annual report and other SEC filings for additional information concerning risk factors that could
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
